Report Overview

Indian Hypophosphatasia (HPP) Treatment Market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Hypophosphatasia (HPP) is one of the rare genetic disorder specialized by the abnormal development of bones and teeth. These abnormalities are occurred due to defective mineralization like calcium and phosphorus. These minerals are needed for proper hardness and strength. Defective mineralization can result in making bones soft and more prone to fracture. It has symptoms which can vary greatly from one person to another, sometimes even among members of the same family. Adult patients with HPP suffer of chronic pain, recurrent fractures and other orthopedics problems, with severe disability that have a serious negative impact on all aspects of their life.



Market Drivers

Increasing number of patients with hypophosphatasia, family history of hypophosphatasia, strong product pipeline, and increasing financial support to researchers for developing new innovative drugs for treatment of hypophosphatasia are likely to drive the hypophosphatasia market during the forecast period. In addition, increase in special designation from the regulatory authorities to offer a treatment to the patients as quickly as possible is enhancing the market.